Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM
British Journal of Haematology, 05/14/2012NatarajanAme S et al. –
The addition of bortezomib to low dose cytarabine arabinoside (LDAC) in higher–risk myelodysplastic syndrome (MDS) may improve results obtained with LDAC alone, especially in patients with unfavourable karyotypes.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.